247 related articles for article (PubMed ID: 34354864)
1. Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Oshi M; Kawaguchi T; Yan L; Peng X; Qi Q; Tian W; Schulze A; McDonald KA; Narayanan S; Young J; Liu S; Morris LG; Chan TA; Kalinski P; Matsuyama R; Otsuji E; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3628-3644. PubMed ID: 34354864
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.
Wu R; Oshi M; Asaoka M; Huyser MR; Tokumaru Y; Yamada A; Yan L; Endo I; Ishikawa T; Takabe K
Am J Cancer Res; 2022; 12(2):744-762. PubMed ID: 35261799
[TBL] [Abstract][Full Text] [Related]
3. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
[TBL] [Abstract][Full Text] [Related]
4. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
[TBL] [Abstract][Full Text] [Related]
5. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
7. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer.
Oshi M; Patel A; Wu R; Le L; Tokumaru Y; Yamada A; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
NPJ Breast Cancer; 2022 Aug; 8(1):92. PubMed ID: 35945417
[TBL] [Abstract][Full Text] [Related]
8. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
[TBL] [Abstract][Full Text] [Related]
9. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
[TBL] [Abstract][Full Text] [Related]
11. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy.
Oshi M; Gandhi S; Huyser MR; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Endo I; Takabe K
Am J Cancer Res; 2021; 11(9):4421-4437. PubMed ID: 34659896
[TBL] [Abstract][Full Text] [Related]
12. Distinct genomic features across cytolytic subgroups in skin melanoma.
Roufas C; Georgakopoulos-Soares I; Zaravinos A
Cancer Immunol Immunother; 2021 Nov; 70(11):3137-3154. PubMed ID: 33779796
[TBL] [Abstract][Full Text] [Related]
13. Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).
Tokumaru Y; Oshi M; Murthy V; Tian W; Yan L; Angarita FA; Nagahashi M; Matsuhashi N; Futamura M; Yoshida K; Miyoshi Y; Takabe K
Am J Cancer Res; 2021; 11(11):5743-5755. PubMed ID: 34873491
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.
Katsuta E; Yan L; Opyrchal M; Kalinski P; Takabe K
Ther Adv Med Oncol; 2021; 13():17588359211006680. PubMed ID: 33868461
[TBL] [Abstract][Full Text] [Related]
15. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
[TBL] [Abstract][Full Text] [Related]
16. Conflicting roles of
Oshi M; Gandhi S; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Ishikawa T; Endo I; Takabe K
Am J Cancer Res; 2021; 11(10):5094-5110. PubMed ID: 34765314
[TBL] [Abstract][Full Text] [Related]
17. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract][Full Text] [Related]
18. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
19. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.
Roufas C; Chasiotis D; Makris A; Efstathiades C; Dimopoulos C; Zaravinos A
Front Oncol; 2018; 8():27. PubMed ID: 29515971
[TBL] [Abstract][Full Text] [Related]
20. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
